EBV Related PTCL clinical trials at UCSF
1 research study open to eligible people
EBV related PTCL is a type of lymphoma caused by the Epstein-Barr virus. UCSF is exploring new treatments for patients with this condition. One trial combines nanatinostat and valganciclovir to evaluate their effectiveness.
Showing trials for
Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
open to eligible people ages 18 years and up
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
San Francisco, California and other locations
Last updated: